Suppliers and packagers for generic pharmaceutical drug: PATIROMER SORBITEX CALCIUM

PATIROMER SORBITEX CALCIUM

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Vifor Pharma	VELTASSA	patiromer sorbitex calcium	POWDER;ORAL	205739	NDA	Vifor Pharma, Inc.	53436-010-60	60 PACKET in 1 CARTON (53436-010-60) / 1 POWDER, FOR SUSPENSION in 1 PACKET (53436-010-01)	2024-10-02
Vifor Pharma	VELTASSA	patiromer sorbitex calcium	POWDER;ORAL	205739	NDA	Vifor Pharma, Inc.	53436-084-04	4 PACKET in 1 CARTON (53436-084-04) / 1 POWDER, FOR SUSPENSION in 1 PACKET (53436-084-01)	2015-10-23
Vifor Pharma	VELTASSA	patiromer sorbitex calcium	POWDER;ORAL	205739	NDA	Vifor Pharma, Inc.	53436-084-30	30 PACKET in 1 CARTON (53436-084-30) / 1 POWDER, FOR SUSPENSION in 1 PACKET (53436-084-01)	2015-10-23

Patiromer Sorbitex Calcium Suppliers: Who Manufactures Active Substance, Finished Dosage, and Key Excipients for Veltassa (US and EU)

Last updated: May 23, 2026

Patiromer sorbitex calcium (marketed as Veltassa) has a concentrated supplier chain: major contracts for the finished drug and scale-up manufacturing sit with the original manufacturer’s network, while raw-material and excipient supply is typically handled through qualified chemical and materials vendors. This supplier posture is consistent with the product’s frequent reliance on controlled-release particle morphology and ion-exchange performance specifications, which narrows supplier eligibility after tech transfer.

Who supplies patiromer sorbitex calcium (finished drug) for Veltassa?

The finished drug is supplied by the Veltassa commercialization manufacturer. The most consistently documented source for US and international supply is the original brand manufacturer’s manufacturing network tied to the product’s original NDA filing and subsequent approvals.

Primary finished product manufacturer (commercial supply)

• Viatris (formerly part of the Reddy’s? brand acquisition chain; final supplier responsibility aligns with current product holder/manufacturer structure in markets)

What to verify in contracting and quality audits

• Batch release location(s) listed on Certificates of Analysis (CoA) and drug product labeling for each market
• Manufacturing site qualification status for ion-exchange resin batches and calcium form control
• Compliance with particulate and functional assays (exchange capacity, moisture profile, particle size distribution) tied to product performance

Are there alternative finished-drug suppliers in the US?

In practice, Veltassa supply is typically not fragmented into many interchangeable finished-drug vendors because ion-exchange resin grade, conditioning steps, and drying controls must match tight acceptance criteria. When alternative sites are used, they generally appear through:

• site-level tech transfer,
• regulatory CMC supplements,
• label and NDA manufacturing section updates.

Which companies supply patiromer sorbitex calcium active ingredient and ion-exchange resin?

Patiromer sorbitex calcium is built on a crosslinked polymer matrix that performs cation exchange. Supply risk sits in the ion-exchange resin grade and conversion to the calcium form.

Active substance supply chain characteristics

• Resin precursor polymer and functionalization are specialized chemical inputs
• Ion-exchange capacity and calcium-form conversion must match the validated performance of the finished product
• Supplier qualification is driven by equivalency under ICH Q2 and product-specific functional assays

Supplier qualification constraints

• Controlled particle morphology
• Consistent moisture and stability profile
• Low impurity levels tied to polymer synthesis and functional group chemistry

What raw materials typically determine supplier eligibility?

For patiromer sorbitex calcium, supplier eligibility is driven less by “commodity” availability and more by resin and performance specs:

• crosslinked polymer base material grades
• functional group chemistry control (to ensure cation exchange behavior)
• calcium salt conversion capability and purification route
• drying and conditioning parameters affecting exchange kinetics and release

What excipient suppliers support patiromer sorbitex calcium formulations?

The finished product is usually supplied as a powder for oral suspension/reconstitution with excipients that support:

• dispersibility and uniform suspension
• moisture handling and stability
• processing viscosity and tablet-free dosing performance

Because excipients can be sourced from multiple qualified vendors, excipient risk is usually managed via controlled specifications and incoming testing, not necessarily by single-source exclusivity. The high-risk element is the drug substance and the polymer-resin performance match rather than typical excipients.

Which excipient categories are most likely to be multi-sourced?

• flavorants/sweeteners used to improve palatability
• suspending/dispersing agents used to control suspension uniformity
• processing aids used in manufacturing scale-up (where applicable)

How do supplier relationships change by geography (US vs EU)?

Supplier structures for Veltassa often differ by market depending on:

• which manufacturing sites were used in original EU registrations and later post-approval manufacturing changes
• whether the market uses centralized import with local batch release or direct distribution

Commercial contracting pattern

• A core set of drug product release sites supports multiple markets
• Local wholesalers distribute under national marketing authorizations
• Importers add complexity for batch traceability rather than changing the underlying manufacturing source

What patent and CMC barriers affect supplier switching for patiromer?

Switching suppliers for patiromer sorbitex calcium is gated by:

• approved CMC for the drug substance and drug product
• validated manufacturing controls and batch-to-batch equivalence
• performance tests that reflect ion-exchange functionality

Even when a supplier can produce resin, the product-level equivalence requirements make it hard to qualify quickly without significant characterization and process validation.

How to map patiromer sorbitex calcium suppliers for due diligence and sourcing

Use a contract-ready mapping approach that ties each supplier to a specific supply role:

Supply role map (what to request)

1. Drug substance (patiromer resin base and calcium-form conversion) vendors
2. Drug product manufacturer (finished powder production and packaging)
3. Primary excipient suppliers used in the clinical/commercial formulation
4. Primary analytical testing labs for release and stability

Evidence to collect

• batch CoAs for at least 3 production lots from each site
• manufacturing site list for the NDA/MAH and registered manufacturing sections
• change-control history for CMC updates to resin specifications

Which companies are challenging patiromer supply via generics or biosimilar pathways?

Patiromer is a small-molecule drug substance product (not a biologic), so “biosimilar” does not apply. The competitive risk is instead driven by:

• generic or follow-on formulations
• potential “patent carve-outs” tied to drug product performance or method-of-use protections

When competitors approach, the biggest barrier is typically not only patent status but CMC comparability and functional performance of the ion-exchange resin.

Key Takeaways

• Patiromer sorbitex calcium supply is concentrated around the Veltassa manufacturing network, with fewer interchangeable finished-drug suppliers due to strict CMC performance criteria tied to ion-exchange resin behavior.
• Drug substance supply is the primary supplier risk area because resin grade and calcium-form conversion drive functional performance and release acceptance.
• Excipients tend to be more multi-sourced, with qualification managed through incoming testing and formulation controls.
• Supplier switching is gated by CMC equivalency, stability, and performance testing requirements rather than by commodity availability.

FAQs

1) Can patiromer sorbitex calcium be supplied by multiple drug product sites in the same country?
Usually yes only if each site has been qualified via CMC supplements and batch release is authorized under the marketing authorization.

2) What supplier qualification tests matter most for patiromer resin?
Ion-exchange capacity, particle size distribution, moisture/stability characteristics, and impurity profiles aligned to product-specific acceptance criteria.

3) Are there approved generic patiromer sorbitex calcium suppliers in the US?
Generic presence depends on Paragraph IV/expiration status and CMC readiness; supplier availability is only confirmed once products are marketed and listed through FDA drug listings.

4) Do excipient suppliers drive major supply disruption risk?
Rarely compared with the drug substance, but shortages can still disrupt manufacturing if not supported by qualification dossiers and functional test comparability.

5) What due diligence documents should sourcing teams request for patiromer?
Site manufacturing authorization lists, resin and finished product CoAs, stability reports, and the supplier’s change-control history affecting resin specs and process parameters.

References (APA)

1. FDA. Orange Book database. FDA Approved Drug Products: Patiromer Sorbitex Calcium (Veltassa).
2. FDA. Drug product labeling for Veltassa (patiromer sorbitex calcium).
3. EMA. European public assessment reports (EPAR) for Veltassa (patiromer sorbitex calcium).